Identification of Avramr1 from Phytophthorainfestans using prolonged be taught and cDNA pathogen-enrichment sequencing (PenSeq)
Potato late blight, introduced on by the oomycete pathogen Phytophthorainfestans, significantly hampers potato manufacturing. Lately, a model new Resistance to Phytophthorainfestans (Rpi) gene, Rpi-amr1, was cloned from a wild Solanum species, Solanumamericanum.
Identification of the corresponding acknowledged effector (Avirulence or Avr) genes from P. infestans is important to elucidating their naturally occurring sequence variation, which in flip informs the potential sturdiness of the cognate late blight resistance. To set up the P. infestans effector acknowledged by Rpi-amr1, we screened obtainable RXLR effector libraries and used prolonged be taught and cDNA pathogen-enrichment sequencing (PenSeq) on Four P. infestans isolates to uncover the untested effectors.
Utilizing single-molecule real-time sequencing (SMRT) and cDNA PenSeq, we acknowledged 47 extraordinarily expressed effectors from P. infestans, along with PITG_07569, which triggers a extraordinarily explicit cell loss of life response when transiently coexpressed with Rpi-amr1 in Nicotianabenthamiana, suggesting that PITG_07569 is Avramr1. Right right here we show that prolonged be taught and cDNA PenSeq permits the identification of full-length RXLR effector households and their expression profile. This study has revealed key insights into the evolution and polymorphism of a flowery RXLR effector family that is associated to the recognition by Rpi-amr1.
Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-2ug |
|||
QP10912-2ug | EnQuireBio | 2ug | EUR 186 |
Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-10ug |
|||
QP10912-10ug | EnQuireBio | 10ug | EUR 241.2 |
Orf virus VEGF-E, Heparin-binding Recombinant Protein |
|||
300-046 | ReliaTech | 20 µg | EUR 194.25 |
Description: A DNA sequence encoding the first 116 amino acid residue of Orf virus VEGF-E isolate D1701 (Dehio et al., 1999 EMBO J. 18:363-374; GenBank accession No. AF106020) was fused with a DNA sequence encoding to the C-terminal heparin binding domain of human VEGF165. The chimeric protein was expressed in insect cells using a baculovirus expression system. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994 J. Virol 68:84-92). Different isolates of orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appear to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999 EMBO J. 18:363-374; Wise et al., 1999 Proc. Natl. Acad. Sci USA 96:3071-3076). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E and hb-VEGF-E can not bind to VEGF receptor-1 (Flt-1). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor–2/ KDR. Compared to human VEGF165 this virus form has no heparin-binding domain and seems to be a freely secreted protein comparable to VEGF121. In order to compare this form with human VEGF165, an additional heparin-binding domain was engineered at the C-terminus to allow interaction with proteo-aminoglycans and heparan sulfate. These form is also able to interact with neuropillin–1. |
Orf virus VEGF-E, Heparin-binding Recombinant Protein |
|||
300-046S | ReliaTech | 5 µg | EUR 94.5 |
Description: A DNA sequence encoding the first 116 amino acid residue of Orf virus VEGF-E isolate D1701 (Dehio et al., 1999 EMBO J. 18:363-374; GenBank accession No. AF106020) was fused with a DNA sequence encoding to the C-terminal heparin binding domain of human VEGF165. The chimeric protein was expressed in insect cells using a baculovirus expression system. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994 J. Virol 68:84-92). Different isolates of orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appear to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999 EMBO J. 18:363-374; Wise et al., 1999 Proc. Natl. Acad. Sci USA 96:3071-3076). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E and hb-VEGF-E can not bind to VEGF receptor-1 (Flt-1). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor–2/ KDR. Compared to human VEGF165 this virus form has no heparin-binding domain and seems to be a freely secreted protein comparable to VEGF121. In order to compare this form with human VEGF165, an additional heparin-binding domain was engineered at the C-terminus to allow interaction with proteo-aminoglycans and heparan sulfate. These form is also able to interact with neuropillin–1. |
VEGF-E Vascular Endothelial Growth Factor-E Recombinant Protein(Orf Virus) |
|||
PROTQ2F842 | BosterBio | Regular: 10ug | EUR 380.4 |
Description: A DNA sequence encoding the mature variant of ovVEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. |
ov-VEGF-E (Orf virus) (Recombinant) Human |
|||
GWB-C8AD60 | GenWay Biotech | 0.005 mg | Ask for price |
VEGFE protein (Orf virus) |
|||
30R-AV011 | Fitzgerald | 5 ug | EUR 381 |
Description: Purified recombinant VEGFE protein (Orf virus) |
Recombinant Orf Virus VEGFE Protein |
|||
VAng-Lsx0417-inquire | Creative Biolabs | inquire | Ask for price |
Description: Orf Virus VEGFE, recombinant protein from Baculovirus. |
Recombinant Orf Virus VEGFE Protein [His] |
|||
VAng-Lsx0418-inquire | Creative Biolabs | inquire | Ask for price |
Description: Orf Virus VEGFE [His], recombinant protein from E. coli. |
Deoxybrevianamide E |
|||
D083-1MG | TOKU-E | 1 mg | EUR 187.71 |
Description: C21H25N3O2 |
Deoxybrevianamide E |
|||
D083-5MG | TOKU-E | 5 mg | EUR 656.34 |
Description: C21H25N3O2 |
Berkeleylactone E |
|||
B087-1MG | TOKU-E | 1 mg | EUR 142.63 |
Description: C20H32O7 |
Berkeleylactone E |
|||
B087-5MG | TOKU-E | 5 mg | EUR 498.97 |
Description: C20H32O7 |
Chevalone E |
|||
C257-0.5MG | TOKU-E | 0.5 mg | EUR 150.43 |
Description: C20H24O4 |
Chevalone E |
|||
C257-2.5MG | TOKU-E | 2.5 mg | EUR 525.85 |
Description: C20H24O4 |
Cytochalasin E |
|||
C197-1MG | TOKU-E | 1 mg | EUR 77.6 |
Description: C28H33NO7 |
Cytochalasin E |
|||
C197-5MG | TOKU-E | 5 mg | EUR 270.51 |
Description: C28H33NO7 |
Roquefortine E |
|||
R035-1MG | TOKU-E | 1 mg | EUR 146.96 |
Description: C27H31N5O2 |
Roquefortine E |
|||
R035-5MG | TOKU-E | 5 mg | EUR 513.71 |
Description: C27H31N5O2 |
Oligomycin E |
|||
O021-1MG | TOKU-E | 1 mg | EUR 207.65 |
Description: C45H72O13 |
Oligomycin E |
|||
O021-5MG | TOKU-E | 5 mg | EUR 726.13 |
Description: C45H72O13 |
Paraherquamide E |
|||
P070-0.5MG | TOKU-E | 0.5 mg | EUR 265.74 |
Description: C28H35N3O4 |
Paraherquamide E |
|||
P070-2.5MG | TOKU-E | 2.5 mg | EUR 928.58 |
Description: C28H35N3O4 |
Phenelfamycin E |
|||
P078-1MG | TOKU-E | 1 mg | EUR 207.65 |
Description: C65H95NO21 |
Phenelfamycin E |
|||
P078-5MG | TOKU-E | 5 mg | EUR 726.13 |
Description: C65H95NO21 |
Azithromycin impurity E EvoPure® |
|||
A074-5MG | TOKU-E | 5 mg | EUR 593.04 |
Description: C36H68N2O12 |
Hepatitis E virus |
|||
Oneq-H498-OneqH498100R | Bioingentech | Oneq-H498-100R | EUR 1028 |
Hepatitis E virus |
|||
Oneq-H498-OneqH498150R | Bioingentech | Oneq-H498-150R | EUR 1438 |
Hepatitis E virus |
|||
Oneq-H498-OneqH49850R | Bioingentech | Oneq-H498-50R | EUR 728 |
Hepatitis E virus |
|||
PCR-H498-PCRH49848R | Bioingentech | PCR-H498-48R | EUR 485 |
Hepatitis E virus |
|||
PCR-H498-PCRH49896R | Bioingentech | PCR-H498-96R | EUR 685 |
Hepatitis E virus ORF 3 Recombinant Protein |
|||
53-335 | ProSci | 0.01 mg | EUR 651.3 |
Description: Hepatitis E virus ORF 3 Recombinant Protein |
Hepatitis E virus ORF 2 Recombinant Protein |
|||
53-336 | ProSci | 0.01 mg | EUR 651.3 |
Description: Hepatitis E virus ORF 2 Recombinant Protein |
Hepatitis E virus ORF 2 Recombinant Protein |
|||
53-337 | ProSci | 0.01 mg | EUR 651.3 |
Description: Hepatitis E virus ORF 2 Recombinant Protein |
Hepatitis E virus ORF 2 recombinant antigen |
|||
8942 | Virostat | 100 ug | EUR 477.6 |
Description: This is Hepatitis E virus ORF 2 recombinant antigen for ELISA,WB. |
Hepatitis E virus ORF 2 recombinant antigen |
|||
8943 | Virostat | 100 ug | EUR 477.6 |
Description: This is Hepatitis E virus ORF 2 recombinant antigen for ELISA,WB. |
Hepatitis E virus ORF 3 recombinant antigen |
|||
8944 | Virostat | 100 ug | EUR 477.6 |
Description: This is Hepatitis E virus ORF 3 recombinant antigen for ELISA,WB. |
Hepatitis E Virus ORF3 Protein |
|||
20-abx260138 | Abbexa |
|
|
Hepatitis E Virus ORF3 Protein |
|||
abx260138-20g | Abbexa | 20 µg | EUR 950 |
Hepatitis E Virus ORF3 Protein |
|||
abx260138-5g | Abbexa | 5 µg | EUR 350 |
Vascular Endothelial Growth Factor-E (Orf Virus) Protein |
|||
20-abx263083 | Abbexa |
|
|
Vascular Endothelial Growth Factor-E (Orf Virus) Protein |
|||
abx263083-10mg | Abbexa | 10 mg | EUR 325 |
Vascular Endothelial Growth Factor-E (Orf Virus) Protein |
|||
abx263083-25mg | Abbexa | 25 mg | EUR 6500 |
Vascular Endothelial Growth Factor-E (Orf Virus) Protein |
|||
abx263083-5mg | Abbexa | 5 mg | EUR 225 |
Hepatitis E Virus ORF3 (Recombinant) |
|||
22060181-1 | Glycomatrix | 100 µg | EUR 264.47 |
Recombinant Hepatitis E Virus ORF3 |
|||
7-07450 | CHI Scientific | 100µg | Ask for price |
Recombinant Hepatitis E Virus ORF3 |
|||
7-07451 | CHI Scientific | 500µg | Ask for price |
Recombinant Hepatitis E Virus ORF3 |
|||
7-07452 | CHI Scientific | 1000µg | Ask for price |
Hepatitis E Virus ORF3 Recombinant |
|||
rAP-5321 | Angio Proteomie | Inquiry | Ask for price |
Vascular Endothelial Growth Factor-E (Orf Virus), (Recombinant) |
|||
22060748-1 | Glycomatrix | 2 µg | EUR 146.42 |
Recombinant Vascular Endothelial Growth Factor-E (Orf Virus) |
|||
7-01759 | CHI Scientific | 2µg | Ask for price |
Recombinant Vascular Endothelial Growth Factor-E (Orf Virus) |
|||
7-01760 | CHI Scientific | 10µg | Ask for price |
Recombinant Vascular Endothelial Growth Factor-E (Orf Virus) |
|||
7-01761 | CHI Scientific | 1mg | Ask for price |
Recombinant Vascular Endothelial Growth Factor-E (Orf Virus) |
|||
cyt-263-10g | ProSpec Tany | 10µg | EUR 145 |
Recombinant Vascular Endothelial Growth Factor-E (Orf Virus) |
|||
cyt-263-1mg | ProSpec Tany | 1mg | EUR 5100 |
Recombinant Vascular Endothelial Growth Factor-E (Orf Virus) |
|||
cyt-263-2g | ProSpec Tany | 2µg | EUR 60 |
Vascular Endothelial Growth Factor-E Recombinant (Orf Virus) |
|||
rAP-2496 | Angio Proteomie | Inquiry | Ask for price |
Hepatitis E virus (ratHEV) |
|||
Oneq-V372-OneqV372100R | Bioingentech | Oneq-V372-100R | EUR 1028 |
Hepatitis E virus (ratHEV) |
|||
Oneq-V372-OneqV372150R | Bioingentech | Oneq-V372-150R | EUR 1438 |
Hepatitis E virus (ratHEV) |
|||
Oneq-V372-OneqV37250R | Bioingentech | Oneq-V372-50R | EUR 728 |
Hepatitis E virus (ratHEV) |
|||
PCR-V372-PCRV37248R | Bioingentech | PCR-V372-48R | EUR 485 |
Hepatitis E virus (ratHEV) |
|||
PCR-V372-PCRV37296R | Bioingentech | PCR-V372-96R | EUR 685 |
Hepatitis E Virus protein |
|||
30-AH29 | Fitzgerald | 1 mg | EUR 895 |
Description: Hepatitis E Virus recombinant protein |
Hepatitis E Virus protein |
|||
30R-AH054X | Fitzgerald | 500 ug | EUR 840 |
Description: Hepatitis E Virus Mosaic recombinant protein |
Hepatitis E Virus antibody |
|||
70R-HR003 | Fitzgerald | 100 ug | EUR 295 |
Description: Affinity purified Rabbit polyclonal Hepatitis E Virus antibody |
West Nile Virus E Prot. |
|||
GWB-41C2BC | GenWay Biotech | 0.1 mg | Ask for price |
Hepatitis E Virus ORF2 (452-617) Protein |
|||
20-abx260268 | Abbexa |
|
|
Hepatitis E Virus ORF2 (633-659) Protein |
|||
20-abx260269 | Abbexa |
|
|
Hepatitis E Virus ORF2 (403-461) Protein |
|||
20-abx260270 | Abbexa |
|
|
Hepatitis E Virus ORF2 (452-617) Protein |
|||
abx260268-20g | Abbexa | 20 µg | EUR 950 |
Hepatitis E Virus ORF2 (452-617) Protein |
|||
abx260268-5g | Abbexa | 5 µg | EUR 350 |
Hepatitis E Virus ORF2 (633-659) Protein |
|||
abx260269-25g | Abbexa | 25 µg | EUR 950 |
Hepatitis E Virus ORF2 (633-659) Protein |
|||
abx260269-5g | Abbexa | 5 µg | EUR 350 |
Hepatitis E Virus ORF2 (403-461) Protein |
|||
abx260270-25g | Abbexa | 25 µg | EUR 950 |
Hepatitis E Virus ORF2 (403-461) Protein |
|||
abx260270-5g | Abbexa | 5 µg | EUR 350 |
Hepatitis E virus PCR kit |
|||
PCR-H498-48R | Bioingentech | 50T | EUR 987.6 |
Hepatitis E virus PCR kit |
|||
PCR-H498-96R | Bioingentech | 100T | EUR 1335.6 |
Hepatitis E Virus ORF2 (452-617), (Recombinant) |
|||
22060180-1 | Glycomatrix | 100 µg | EUR 264.47 |
Hepatitis E Virus ORF2 (403-461), (Recombinant) |
|||
22060182-1 | Glycomatrix | 100 µg | EUR 264.47 |
Hepatitis E Virus ORF2 (633-659), (Recombinant) |
|||
22060183-1 | Glycomatrix | 100 µg | EUR 264.47 |
Recombinant Hepatitis E Virus ORF2 (633-659) |
|||
7-07441 | CHI Scientific | 100µg | Ask for price |
Recombinant Hepatitis E Virus ORF2 (633-659) |
|||
7-07442 | CHI Scientific | 500µg | Ask for price |
Recombinant Hepatitis E Virus ORF2 (633-659) |
|||
7-07443 | CHI Scientific | 1000µg | Ask for price |
Recombinant Hepatitis E Virus ORF2 (403-461) |
|||
7-07444 | CHI Scientific | 100µg | Ask for price |
Recombinant Hepatitis E Virus ORF2 (403-461) |
|||
7-07445 | CHI Scientific | 500µg | Ask for price |
Recombinant Hepatitis E Virus ORF2 (403-461) |
|||
7-07446 | CHI Scientific | 1000µg | Ask for price |
Recombinant Hepatitis E Virus ORF2 (452-617) |
|||
7-07447 | CHI Scientific | 100µg | Ask for price |
Recombinant Hepatitis E Virus ORF2 (452-617) |
|||
7-07448 | CHI Scientific | 500µg | Ask for price |
Recombinant Hepatitis E Virus ORF2 (452-617) |
|||
7-07449 | CHI Scientific | 1000µg | Ask for price |
Hepatitis E Virus protein (HRP) |
|||
65-IH35 | Fitzgerald | 1 ml | EUR 1100 |
Description: Purified recombinant Hepatitis E Virus protein (HRP) |
Recombinant Zika Virus E Protein |
|||
VAng-Lsx0581-100g | Creative Biolabs | 100 µg | EUR 1365.6 |
Description: Zika Virus Envelope, recombinant protein from Insect cells. |
Anti-Hepatitis E Virus Antibody |
|||
18606 | Genovis AB | 100ug | EUR 397 |
Hantaan Virus Nucleoprotein (E. coli) |
|||
REC31725-100 | The Native Antigen Company | 0.1 | EUR 348.29 |
Description: Hantavirus Nucleocapsid (N) protein produced in E. coli. |
Hantaan Virus Nucleoprotein (E. coli) |
|||
REC31725-500 | The Native Antigen Company | 0.5 | EUR 1217.07 |
Description: Hantavirus Nucleocapsid (N) protein produced in E. coli. |
Recombinant (E.Coli) Hepatitis E Virus (HEV) ORF3 |
|||
RP-531 | Alpha Diagnostics | 100 ug | EUR 343.2 |
Hepatitis E Virus Mosaic Recombinant |
|||
rAP-5317 | Angio Proteomie | Inquiry | Ask for price |
Hepatitis E virus RT PCR kit |
|||
RTq-H498-100R | Bioingentech | 100T | EUR 1573.2 |
Hepatitis E virus RT PCR kit |
|||
RTq-H498-150R | Bioingentech | 150T | EUR 2144.4 |
Hepatitis E virus RT PCR kit |
|||
RTq-H498-50R | Bioingentech | 50T | EUR 1155.6 |
Hepatitis E Virus ORF2 (452-617 a.a.) Recombinant |
|||
rAP-5318 | Angio Proteomie | Inquiry | Ask for price |
Hepatitis E Virus ORF2 (633-659 a.a.) Recombinant |
|||
rAP-5319 | Angio Proteomie | Inquiry | Ask for price |
Hepatitis E Virus ORF2 (403-461 a.a.) Recombinant |
|||
rAP-5320 | Angio Proteomie | Inquiry | Ask for price |
VEGF (165): Human Recombinant E Coli |
|||
GWB-BDEFEF | GenWay Biotech | 1 mg | Ask for price |
OPPA00528-2UG - VEGF E Protein |
|||
OPPA00528-2UG | Aviva Systems Biology | 2ug | EUR 70 |
Hepatitis E virus (ratHEV) PCR kit |
|||
PCR-V372-48R | Bioingentech | 50T | EUR 987.6 |
Hepatitis E virus (ratHEV) PCR kit |
|||
PCR-V372-96R | Bioingentech | 100T | EUR 1335.6 |
Hepatitis E virus genotype 1 Protein ORF3 (ORF3) |
|||
1-CSB-EP527126HVZ | Cusabio |
|
|
Description: Recombinant Hepatitis E virus genotype 1 Protein ORF3 (ORF3) expressed in E.coli |
Hepatitis B Virus E Antigen (HBeAg) |
|||
REC31677-100 | The Native Antigen Company | 0.1 | EUR 456.72 |
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
Hepatitis B Virus E Antigen (HBeAg) |
|||
REC31677-500 | The Native Antigen Company | 0.5 | EUR 1941.06 |
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
Viridicatin |
|||
V023-1MG | TOKU-E | 1 mg | EUR 146.96 |
Description: C15H11NO2 |
Viridicatin |
|||
V023-5MG | TOKU-E | 5 mg | EUR 513.71 |
Description: C15H11NO2 |
Virginiamycin S1 |
|||
V014-25MG | TOKU-E | 25 mg | EUR 756.48 |
Description: C43H49N7O10 |
Virginiamycin S1 |
|||
V014-5MG | TOKU-E | 5 mg | EUR 216.32 |
Description: C43H49N7O10 |
Virginiamycin B |
|||
V021-25MG | TOKU-E | 25 mg | EUR 943.76 |
Description: C45H54N8O10 |
Virginiamycin B |
|||
V021-5MG | TOKU-E | 5 mg | EUR 207.65 |
Description: C45H54N8O10 |
Virginiamycin |
|||
V022-25MG | TOKU-E | 25 mg | EUR 751.28 |
Description: C28H35N3O7 (for M1) C43H49N7O10 (for S1) |
Virginiamycin |
|||
V022-5MG | TOKU-E | 5 mg | EUR 214.59 |
Description: C28H35N3O7 (for M1) C43H49N7O10 (for S1) |
Virginiamycin >95% |
|||
V030-100MG | TOKU-E | 100mg | EUR 207.03 |
Description: C28H35N3O7(for M1) C43H49N7O10(for S1) |
Virginiamycin >95% |
|||
V030-500MG | TOKU-E | 500mg | EUR 421.47 |
Description: C28H35N3O7(for M1) C43H49N7O10(for S1) |
Zika Virus Envelope (ZIKV E) Antibody |
|||
abx201401-100l | Abbexa | 100 µl | EUR 450 |
Zika Virus Envelope (ZIKV E) Antibody |
|||
abx201401-50l | Abbexa | 50 µl | EUR 312.5 |
Zika Virus Envelope (ZIKV E) Antibody |
|||
abx201402-100l | Abbexa | 100 µl | EUR 450 |
Zika Virus Envelope (ZIKV E) Antibody |
|||
abx201402-50l | Abbexa | 50 µl | EUR 312.5 |
Hepatitis E Virus ORF 2 Recombinant Protein beta-galactosidase liquid |
|||
IHEPEHEPEORF2R10UG | Innovative research | each | EUR 762 |
Description: Hepatitis E Virus ORF 2 Recombinant Protein beta-galactosidase liquid |
Hepatitis E Virus ORF 3 Recombinant Protein beta-galactosidase liquid |
|||
IHEPEHEPEORF3R10UG | Innovative research | each | EUR 762 |
Description: Hepatitis E Virus ORF 3 Recombinant Protein beta-galactosidase liquid |
Hepatitis E Virus Capsid Protein (ORF2), His-tag |
|||
REC31653-100 | The Native Antigen Company | 0.1 | EUR 354.66 |
Description: Recombinant Hepatitis E (HEV) ORF2. Protein contains a C-terminal His-tag. |
Hepatitis E Virus Capsid Protein (ORF2), His-tag |
|||
REC31653-500 | The Native Antigen Company | 0.5 | EUR 1252.79 |
Description: Recombinant Hepatitis E (HEV) ORF2. Protein contains a C-terminal His-tag. |
Viridicatumtoxin |
|||
V024-1MG | TOKU-E | 1 mg | EUR 207.65 |
Description: C30H31NO10 |
Viridicatumtoxin |
|||
V024-5MG | TOKU-E | 5 mg | EUR 726.13 |
Description: C30H31NO10 |
Dengue virus 1 E recombinant antigen |
|||
8812 | Virostat | 100 ug | EUR 477.6 |
Description: This is Dengue virus 1 E recombinant antigen for ELISA,WB. |
Dengue virus 2 E recombinant antigen |
|||
8813 | Virostat | 100 ug | EUR 477.6 |
Description: This is Dengue virus 2 E recombinant antigen for ELISA,WB. |
Dengue virus 3 E recombinant antigen |
|||
8814 | Virostat | 100 ug | EUR 477.6 |
Description: This is Dengue virus 3 E recombinant antigen for ELISA,WB. |
Dengue virus 4 E recombinant antigen |
|||
8815 | Virostat | 100 ug | EUR 477.6 |
Description: This is Dengue virus 4 E recombinant antigen for ELISA,WB. |
Hepatitis B Virus e-Antigen Protein |
|||
20-abx260781 | Abbexa |
|
|
Hepatitis B Virus E Antigen Antibody |
|||
20-abx134030 | Abbexa |
|
|
Equine uridine diphospho-glucuronosyltransferase 1A1, 2A1, 2B4, 2B31: cDNA cloning, expression and initial characterization of morphine metabolism
Goal: Uridine diphospho-glucuronosyltransferases (UGTs) are membrane-bound enzymes that catalyze the conjugation of glucuronic acid onto a numerous set of xenobiotics. Horses successfully and extensively glucuronidate so much of xenobiotics, along with opioids, making UGTs an very important group of drug-metabolizing enzymes for the clearance of remedy. Recombinant enzymes have allowed researchers to characterize the metabolism of a variety of remedy. The first purpose was to clone, particular and characterize equine UGTs using remedy characterised as UGT substrates in numerous species. A secondary purpose was to characterize the in vitro metabolism of morphine in horses.
Examine design: In vitro drug metabolism study using liver microsomes and recombinant enzyme strategies.
Animals: Liver microsomes and RNA from tissue collected from two Thoroughbred mares euthanized for various causes.
Strategies: Primarily based on homology to the human UGT2B7, Four equine UGT variants have been expressed: UGT1A1, UGT2A1, UGT2B31 and UGT2B4. cDNA sequences have been cloned and ensuing protein expressed in a baculovirus expression system. Performance of the enzymes was assessed using 4-methylumbelliferone, testosterone, diclofenac and ketoprofen. Recombinant enzyme, administration cells, equine liver microsomes and human UGT2B7 supersomes have been then incubated with morphine. Concentrations of metabolites have been measured using liquid chromatography-tandem mass spectrometry and enzyme kinetics determined.
Outcomes: 4-Methylumbelliferone was glucuronidated by all expressed equine UGTs. Testosterone glucuronide was not produced by any of the expressed enzymes, and diclofenac glucuronide and ketoprofen glucuronide have been produced by UG2A1 and UGT1A1, respectively. UGT2B31 metabolized morphine to morphine-3-glucuronide and low concentrations of morphine-6-glucuronide.
Conclusions and scientific relevance: That is the first worthwhile expression of helpful recombinant equine UGTs. UGT2B31 contributes to the glucuronidation of morphine; nonetheless, it is possibly not the first metabolizing enzyme. These outcomes warrant further investigation of equine UGTs, along with expression of additional enzymes and extra characterization of UGT2B31 as a contributor to morphine metabolism.
An progressive genosensor for the monitoring of Leishmaniaspp sequence using binding of pDNA to cDNA primarily based on Cit-AgNPs
Leishmaniasis thought of as primarily probably the most important epidemic-prone diseases based on the World Well being Group. Early diagnoses and treatment of Leishmania an an infection is an efficient downside since, it has no symptom and is resistance to remedy. Subsequently, there’s an urgent need for delicate and precise detection of this pathogen.
On this study, a model new method was developed for optical biosensing of Leishmaniaspp sequence primarily based on hybridization of Citrate capped Ag nanoparticles bonded to explicit single stranded DNA probe of Leishmania spp. Aggregation of the Citrate capped Ag nanoparticles throughout the existence or lack of a cDNA sequence of Leishmania, set off eye catching and considerable very important alter throughout the UV-vis.
The obtained low prohibit of quantification (LLOQ) of was achieved as 1ZM. Primarily based on experimental ends in optimum conditions, quick bioanalysis of Leishmaniaspp sequence was carried out (2 min). So, this probe could be utilized for the scientific evaluation of this pathogen and an an infection sickness.
Recombinant Orf Virus VEGFE Protein [His] |
|||
VAng-Lsx0418-inquire | Creative Biolabs | inquire | Ask for price |
Description: Orf Virus VEGFE [His], recombinant protein from E. coli. |
Orf virus VEGF-E Recombinant Protein |
|||
300-044 | ReliaTech | 5 µg | EUR 136.5 |
Description: A DNA sequence encoding the mature variant of ov-VEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight Cysteine residues of the central Cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999; Wise et al., 1999). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E cannot bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR. |
Orf virus VEGF-E Recombinant Protein |
|||
300-044S | ReliaTech | 2 µg | EUR 73.5 |
Description: A DNA sequence encoding the mature variant of ovVEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999; Wise et al., 1999). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E can not bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR. |
Orf virus VEGF-E Recombinant Protein |
|||
300-045 | ReliaTech | 20 µg | EUR 357 |
Description: A DNA sequence encoding the mature variant of ovVEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999; Wise et al., 1999). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E can not bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR. |
Orf virus VEGF-E, Heparin-binding Recombinant Protein |
|||
300-046 | ReliaTech | 20 µg | EUR 194.25 |
Description: A DNA sequence encoding the first 116 amino acid residue of Orf virus VEGF-E isolate D1701 (Dehio et al., 1999 EMBO J. 18:363-374; GenBank accession No. AF106020) was fused with a DNA sequence encoding to the C-terminal heparin binding domain of human VEGF165. The chimeric protein was expressed in insect cells using a baculovirus expression system. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994 J. Virol 68:84-92). Different isolates of orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appear to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999 EMBO J. 18:363-374; Wise et al., 1999 Proc. Natl. Acad. Sci USA 96:3071-3076). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E and hb-VEGF-E can not bind to VEGF receptor-1 (Flt-1). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor–2/ KDR. Compared to human VEGF165 this virus form has no heparin-binding domain and seems to be a freely secreted protein comparable to VEGF121. In order to compare this form with human VEGF165, an additional heparin-binding domain was engineered at the C-terminus to allow interaction with proteo-aminoglycans and heparan sulfate. These form is also able to interact with neuropillin–1. |
Orf virus VEGF-E, Heparin-binding Recombinant Protein |
|||
300-046S | ReliaTech | 5 µg | EUR 94.5 |
Description: A DNA sequence encoding the first 116 amino acid residue of Orf virus VEGF-E isolate D1701 (Dehio et al., 1999 EMBO J. 18:363-374; GenBank accession No. AF106020) was fused with a DNA sequence encoding to the C-terminal heparin binding domain of human VEGF165. The chimeric protein was expressed in insect cells using a baculovirus expression system. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV) (Lyttle et al., 1994 J. Virol 68:84-92). Different isolates of orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appear to be derived from captured host genes. All eight cysteine residues of the central cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins (Dehio et al., 1999 EMBO J. 18:363-374; Wise et al., 1999 Proc. Natl. Acad. Sci USA 96:3071-3076). Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E and hb-VEGF-E can not bind to VEGF receptor-1 (Flt-1). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor–2/ KDR. Compared to human VEGF165 this virus form has no heparin-binding domain and seems to be a freely secreted protein comparable to VEGF121. In order to compare this form with human VEGF165, an additional heparin-binding domain was engineered at the C-terminus to allow interaction with proteo-aminoglycans and heparan sulfate. These form is also able to interact with neuropillin–1. |
VEGF-E Vascular Endothelial Growth Factor-E Recombinant Protein(Orf Virus) |
|||
PROTQ2F842 | BosterBio | Regular: 10ug | EUR 380.4 |
Description: A DNA sequence encoding the mature variant of ovVEGF-E isolate D1701 (Dehio et al., 1999; GenBank accession No. AF106020) was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. |
Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-1mg |
|||
QP10912-1mg | EnQuireBio | 1mg | EUR 6181.2 |
Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-2ug |
|||
QP10912-2ug | EnQuireBio | 2ug | EUR 186 |
Recombinant Virus VEGF E (Orf Virus) Protein, His, E.coli-10ug |
|||
QP10912-10ug | EnQuireBio | 10ug | EUR 241.2 |
Anti-Orf Virus VEGF-E Antibody |
|||
102-PA70 | ReliaTech | 50 µg | EUR 115.5 |
Description: A DNA sequence encoding the mature variant of ov-VEGF-E isolate D1701 was expressed in E. coli as a 132 amino acid residue fusion protein with an N-terminal His-tag sequence and a thrombin cleavage site. Recombinant VEGF-E homodimer was dimerized in vitro and has a predicted mass of approximately 35 kDa. Based on sequence similarity to VEGF-A, a gene encoding a VEGF homologue has recently been discovered in the genome of Orf virus (OV). Different isolates of Orf virus show significant amino acid sequence similarity to VEGF-A and described as a viral virulence factor that appears to be derived from captured host genes. All eight Cysteine residues of the central Cysteine knot motif characteristic of members of the VEGF family are conserved among other residues in the VEGF-E proteins. Alignment of all mammalian VEGF sequences indicated that VEGF-E is distinct from the previously described VEGFs but most closely related to VEGF-A. Like VEGF-A, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation, whilst in contrast to VEGF-A, VEGF-E cannot bind to VEGF receptor-1 (Flt-1). Furthermore VEGF-E can also not bind to VEGF receptor-3 (FLT-4). Therefore VEGF-E is a potent angiogenic factor selectively binding to VEGF receptor –2/KDR. |
VEGF E (Orf Virus) |
|||
cyt-263 | ProSpec Tany | 2µg | EUR 60 |
Description: Recombinant Vascular Endothelial Growth Factor-E (Orf Virus) |
Human PDGFC / VEGFE, Fc Tag |
|||
E24PHA208 | EnoGene | 50 μg | EUR 180 |
Human PDGFC / VEGFE, His Tag |
|||
E24PHA209 | EnoGene | 50 μg | EUR 225 |
Cynomolgus / Rhesus Macaque PDGFC / VEGFE, Fc Tag |
|||
E24PCA081 | EnoGene | 50 μg | EUR 180 |
Cynomolgus / Rhesus Macaque PDGFC / VEGFE, His Tag |
|||
E24PCA082 | EnoGene | 50 μg | EUR 225 |
Virus Measles Virus (MeV) Protein |
|||
abx670263-1ml | Abbexa | 1 ml | EUR 543.6 |
Virus West Nile Virus (WNV) Protein |
|||
abx670276-100ug | Abbexa | 100 ug | EUR 794.4 |
Virus Hepatitis A Virus (HAV) Protein |
|||
abx670259-1ml | Abbexa | 1 ml | EUR 427.2 |
Virus Yellow Fever Virus (YFV) Protein |
|||
abx670277-100ug | Abbexa | 100 ug | EUR 644.4 |
Virus Varicella Zoster Virus (VZV) Protein |
|||
abx670269-1ml | Abbexa | 1 ml | EUR 794.4 |
Hepatitis E virus ORF 3 Recombinant Protein |
|||
53-335 | ProSci | 0.01 mg | EUR 651.3 |
Description: Hepatitis E virus ORF 3 Recombinant Protein |
Hepatitis E virus ORF 2 Recombinant Protein |
|||
53-336 | ProSci | 0.01 mg | EUR 651.3 |
Description: Hepatitis E virus ORF 2 Recombinant Protein |
Hepatitis E virus ORF 2 Recombinant Protein |
|||
53-337 | ProSci | 0.01 mg | EUR 651.3 |
Description: Hepatitis E virus ORF 2 Recombinant Protein |
Virus Respiratory Syncytial Virus (RSV) Protein |
|||
abx670078-01mg | Abbexa | 0.1 mg | EUR 594 |
Virus Parainfluenza Virus 1 (HPIV-1) Protein |
|||
abx670265-1ml | Abbexa | 1 ml | EUR 794.4 |
Virus Parainfluenza Virus 2 (HPIV-2) Protein |
|||
abx670266-1ml | Abbexa | 1 ml | EUR 710.4 |
Virus Parainfluenza Virus 3 (HPIV-3) Protein |
|||
abx670267-1ml | Abbexa | 1 ml | EUR 710.4 |
Rat virus protein |
|||
30-1272 | Fitzgerald | 1 mg | EUR 195 |
Description: Purified native Rat virus protein (Mouse) |
Vascular Endothelial Growth Factor-E (Orf Virus) Protein |
|||
20-abx263083 | Abbexa |
|
|
Vascular Endothelial Growth Factor-E (Orf Virus) Protein |
|||
abx263083-10mg | Abbexa | 10 mg | EUR 325 |
Vascular Endothelial Growth Factor-E (Orf Virus) Protein |
|||
abx263083-25mg | Abbexa | 25 mg | EUR 6500 |
Vascular Endothelial Growth Factor-E (Orf Virus) Protein |
|||
abx263083-5mg | Abbexa | 5 mg | EUR 225 |
Virus Herpes Simplex Virus 2 (HSV-2) Protein |
|||
abx670261-1ml | Abbexa | 1 ml | EUR 360 |
Mumps virus protein |
|||
30-1309 | Fitzgerald | 1 mg | EUR 245 |
Description: Purified native Mumps virus protein |
Mumps virus protein |
|||
30-1310 | Fitzgerald | 1 mg | EUR 200 |
Description: Purified native Mumps virus protein |
Mumps virus protein |
|||
30-AM18 | Fitzgerald | 1 ml | EUR 234 |
Description: Purified Mumps virus protein |
Mumps virus protein |
|||
30R-AM029 | Fitzgerald | 1 ml | EUR 553 |
Description: Purified native Mumps virus protein |
Mumps Virus Protein |
|||
abx670264-1ml | Abbexa | 1 ml | EUR 543.6 |
Mumps Virus Protein |
|||
abx670264-100g | Abbexa | 100 µg | EUR 362.5 |
Sendai virus protein |
|||
DAGA-514 | Creative Diagnostics | 1mg | EUR 664.8 |
Hepatitis E Virus ORF3 Protein |
|||
20-abx260138 | Abbexa |
|
|
Hepatitis E Virus ORF3 Protein |
|||
abx260138-20g | Abbexa | 20 µg | EUR 950 |
Hepatitis E Virus ORF3 Protein |
|||
abx260138-5g | Abbexa | 5 µg | EUR 350 |
Measles virus protein |
|||
30-1308 | Fitzgerald | 1 mg | EUR 200 |
Description: Purified native Measles virus protein |
Rubella virus protein |
|||
30-1344 | Fitzgerald | 1 ml | EUR 497 |
Description: Purified native Rubella virus protein (Grade III) |
Rubeola virus protein |
|||
30-AR23 | Fitzgerald | 1 ml | EUR 287 |
Description: Purified Rubeola virus protein |
Rubella Virus Protein |
|||
abx670270-1mg | Abbexa | 1 mg | EUR 1212 |
Rubella Virus Protein |
|||
abx670271-1mg | Abbexa | 1 mg | EUR 2163.6 |
Varicella Zoster Virus ORF26 Protein |
|||
20-abx260176 | Abbexa |
|
|
Varicella Zoster Virus ORF26 Protein |
|||
abx260176-20g | Abbexa | 20 µg | EUR 950 |
Varicella Zoster Virus ORF26 Protein |
|||
abx260176-5g | Abbexa | 5 µg | EUR 350 |
Anti-PDGFC / VEGFE Reference Antibody (Thrombogenics anti-PDGF-C) |
|||
E24CHA317 | EnoGene | 100 μg | EUR 225 |
Description: Available in various conjugation types. |
Varicella Zoster Virus ORF9 Protein |
|||
20-abx260175 | Abbexa |
|
|
Varicella Zoster Virus ORF9 Protein |
|||
abx260175-20g | Abbexa | 20 µg | EUR 950 |
Varicella Zoster Virus ORF9 Protein |
|||
abx260175-5g | Abbexa | 5 µg | EUR 350 |
Virus Herpes Simplex Virus 1 (HSV-1 Antibody) Protein |
|||
abx670260-1ml | Abbexa | 1 ml | EUR 360 |
Zika Virus NS1 Protein |
|||
abx061380-1mg | Abbexa | 1 mg | EUR 1722 |
Zika virus NS1 protein |
|||
30-1931 | Fitzgerald | 100 ug | EUR 3450 |
Description: Recombinant Zika virus NS1 protein |
Zika virus NS1 protein |
|||
30-1936 | Fitzgerald | 100 ug | EUR 1700 |
Description: Recombinant Zika virus NS1 protein with His tag |
Nipah Virus G Protein |
|||
abx160012-100ug | Abbexa | 100 ug | EUR 661.2 |
Zika virus NS1 Protein |
|||
E40VAG345 | EnoGene | 20ug | EUR 495 |
Ebola Virus NP protein |
|||
80-1411 | Fitzgerald | 100 ug | EUR 132 |
Description: Purified Recombinant Ebola Nucleoprotein antigen (Zaire strain) |
Zika Virus NS1 Protein |
|||
abx061380-100g | Abbexa | 100 µg | Ask for price |
Zika Virus NS1 Protein |
|||
abx061380-10g | Abbexa | 10 µg | EUR 1725 |
Zika Virus NS1 Protein |
|||
abx061380-50g | Abbexa | 50 µg | Ask for price |
Usutu Virus NS1 Protein |
|||
USUV-NS1-100 | The Native Antigen Company | 0.1 | EUR 473.31 |
Description: Recombinant Usutu Virus NS1 protein produced in 293 human cells. Protein contains a C-terminal His-tag. |
Usutu Virus NS1 Protein |
|||
USUV-NS1-500 | The Native Antigen Company | 0.5 | EUR 1802.64 |
Description: Recombinant Usutu Virus NS1 protein produced in 293 human cells. Protein contains a C-terminal His-tag. |
Hepatitis E Virus ORF2 (452-617) Protein |
|||
20-abx260268 | Abbexa |
|
|
Hepatitis E Virus ORF2 (633-659) Protein |
|||
20-abx260269 | Abbexa |
|
|
Hepatitis E Virus ORF2 (403-461) Protein |
|||
20-abx260270 | Abbexa |
|
|
Hepatitis E Virus ORF2 (452-617) Protein |
|||
abx260268-20g | Abbexa | 20 µg | EUR 950 |
Hepatitis E Virus ORF2 (452-617) Protein |
|||
abx260268-5g | Abbexa | 5 µg | EUR 350 |
Hepatitis E Virus ORF2 (633-659) Protein |
|||
abx260269-25g | Abbexa | 25 µg | EUR 950 |
Hepatitis E Virus ORF2 (633-659) Protein |
|||
abx260269-5g | Abbexa | 5 µg | EUR 350 |
Hepatitis E Virus ORF2 (403-461) Protein |
|||
abx260270-25g | Abbexa | 25 µg | EUR 950 |
Hepatitis E Virus ORF2 (403-461) Protein |
|||
abx260270-5g | Abbexa | 5 µg | EUR 350 |
Rubella Virus E2 Protein |
|||
abx060648-1mg | Abbexa | 1 mg | EUR 2055.6 |
Rubella Virus E2 Protein |
|||
abx060649-1mg | Abbexa | 1 mg | EUR 1713.6 |
Rubella virus E2 protein |
|||
30-1281 | Fitzgerald | 1 mg | EUR 1195 |
Description: Purified recombinant Rubella virus E2 protein |
Ebola Virus VP40 protein |
|||
30-1837 | Fitzgerald | 100 ug | EUR 136 |
Description: Recombinant Ebola Virus VP40 Matrix protein |
Rubella Virus E2 Protein |
|||
20-abx260148 | Abbexa |
|
|
Rubella virus E2 protein |
|||
DAGA-498 | Creative Diagnostics | 1mg | EUR 3385.2 |
Rubella Virus E1 protein |
|||
80-1059 | Fitzgerald | 1 mg | EUR 1680 |
Description: Purified recombinant Rubella Virus E1 protein |
Rubella Virus E2 Protein |
|||
abx260148-20g | Abbexa | 20 µg | EUR 950 |
Rubella Virus E2 Protein |
|||
abx260148-5g | Abbexa | 5 µg | EUR 350 |
Norwalk virus Capsid protein VP1 (ORF2) |
|||
1-CSB-YP767779NBAY | Cusabio |
|
|
Description: Recombinant Norwalk virus Capsid protein VP1(ORF2) expressed in Yeast |
Norwalk virus Capsid protein VP1 (ORF2) |
|||
1-CSB-MP767779NBAY | Cusabio |
|
|
Description: Recombinant Norwalk virus Capsid protein VP1(ORF2) expressed in Mammalian cell |
Dengue Virus Typ1 Protein |
|||
abx069812-100ug | Abbexa | 100 ug | EUR 1161.6 |
Dengue Virus Typ1 Protein |
|||
abx069812-25g | Abbexa | 25 g | Ask for price |
Dengue Virus Typ1 Protein |
|||
abx069812-5g | Abbexa | 5 g | EUR 1150 |
Measles Virus (MeV) Protein |
|||
abx670263-100g | Abbexa | 100 µg | EUR 362.5 |
Hepatitis D Virus Protein |
|||
abx060542-1mg | Abbexa | 1 mg | EUR 1888.8 |
Hepatitis A Virus protein |
|||
30-1929 | Fitzgerald | 1 ml | EUR 95 |
Description: Purified Native Hepatitis A Virus protein |
Hepatitis C Virus protein |
|||
30-1989 | Fitzgerald | 1 mg | EUR 595 |
Description: Purified recombinant Hepatitis C Virus protein |
Hepatitis C Virus protein |
|||
30-1990 | Fitzgerald | 1 mg | EUR 595 |
Description: Purified recombinant Hepatitis C Virus protein |
Hepatitis C Virus protein |
|||
30-1991 | Fitzgerald | 1 mg | EUR 595 |
Description: Purified recombinant Hepatitis C Virus protein |
Hepatitis E Virus protein |
|||
30-AH29 | Fitzgerald | 1 mg | EUR 895 |
Description: Hepatitis E Virus recombinant protein |
Hepatitis C Virus protein |
|||
30-AH64 | Fitzgerald | 1 mg | EUR 495 |
Description: Purified recombinant Hepatitis C Virus protein |
Hepatitis C Virus protein |
|||
30-AH66 | Fitzgerald | 1 mg | EUR 168 |
Description: Purified recombinant Hepatitis C Virus protein |
Hepatitis C Virus protein |
|||
30-AH67 | Fitzgerald | 1 mg | EUR 807.6 |
Description: Purified recombinant Hepatitis C Virus protein |
Hepatitis C Virus protein |
|||
30-AH68 | Fitzgerald | 1 mg | EUR 168 |
Description: Purified recombinant Hepatitis C Virus protein |
Hepatitis C Virus protein |
|||
30-AH72 | Fitzgerald | 1 mg | EUR 695 |
Description: Purified recombinant Hepatitis C Virus protein |
Hepatitis C Virus protein |
|||
30-AH95 | Fitzgerald | 1 mg | EUR 400 |
Description: Purified recombinant Hepatitis C Virus Core protein |
Hepatitis A Virus protein |
|||
30R-AH015 | Fitzgerald | 1 ml | EUR 1028 |
Description: Purified native Hepatitis A Virus protein |
Hepatitis E Virus protein |
|||
30R-AH054X | Fitzgerald | 500 ug | EUR 840 |
Description: Hepatitis E Virus Mosaic recombinant protein |
Hepatitis D Virus protein |
|||
30R-AH055X | Fitzgerald | 500 ug | EUR 875 |
Description: Hepatitis D Virus recombinant protein |
Hepatitis D Virus Protein |
|||
20-abx260136 | Abbexa |
|
|
Powassan Virus NS1 Protein |
|||
REC31643-100 | The Native Antigen Company | 0.1 | EUR 473.31 |
Description: Recombinant Powassan Virus NS1 protein produced in 293 human cells. Protein contains a C-terminal 6x His-tag. The oligomerisation state is predominantly hexameric. |
Powassan Virus NS1 Protein |
|||
REC31643-500 | The Native Antigen Company | 0.5 | EUR 1890.66 |
Description: Recombinant Powassan Virus NS1 protein produced in 293 human cells. Protein contains a C-terminal 6x His-tag. The oligomerisation state is predominantly hexameric. |
Hepatitis D Virus Protein |
|||
abx060542-5mg | Abbexa | 5 mg | Ask for price |
Hepatitis D Virus Protein |
|||
abx260136-10g | Abbexa | 10 µg | EUR 950 |
Hepatitis D Virus Protein |
|||
abx260136-2g | Abbexa | 2 µg | EUR 350 |
Zika Virus Envelope Protein |
|||
abx061381-1mg | Abbexa | 1 mg | EUR 1722 |
Polyoma virus protein (Mouse) |
|||
30-1271 | Fitzgerald | 1 mg | EUR 195 |
Description: Purified native Polyoma virus protein |
Zika virus envelope protein |
|||
30-1932 | Fitzgerald | 100 ug | EUR 3400 |
Description: Recombinant Zika virus envelope protein |
Zika virus envelope protein |
|||
30-1935 | Fitzgerald | 100 ug | EUR 1700 |
Description: Recombinant Zika virus envelope protein |
Zika Virus Envelope Protein |
|||
abx160022-1mg | Abbexa | 1 mg | EUR 1746 |
Zika Virus Envelope Protein |
|||
abx061381-100g | Abbexa | 100 µg | Ask for price |
Zika Virus Envelope Protein |
|||
abx061381-10g | Abbexa | 10 µg | EUR 1725 |
Zika Virus Envelope Protein |
|||
abx061381-50g | Abbexa | 50 µg | Ask for price |
Rubella Virus Capsid Protein |
|||
abx060645-1mg | Abbexa | 1 mg | EUR 2180.4 |
Mouse Leukemia virus protein |
|||
30-1273 | Fitzgerald | 1 mg | EUR 195 |
Description: Purified native Mouse Leukemia virus protein |
Chikungunya virus E1 protein |
|||
30-1942 | Fitzgerald | 100 ug | EUR 1500 |
Description: Recombinant Chikungunya virus E1 protein - wild type |
Virus Adenovirus (ADV) Protein |
|||
abx670001-1ml | Abbexa | 1 ml | EUR 744 |
Virus Hepatitis B Virus Surface Antigen ay (HBsAg ay) Protein |
|||
abx670099-01mg | Abbexa | 0.1 mg | EUR 678 |
Virus Hepatitis B Virus Surface Antigen ad (HBsAg ad) Protein |
|||
abx670255-01mg | Abbexa | 0.1 mg | EUR 844.8 |
Wesselsbron Virus NS1 protein |
|||
REC31698-100 | The Native Antigen Company | 0.1 | EUR 473.31 |
Description: Recombinant Wesselsbron Virus NS1 protein produced in 293 human cells. Protein contains a C-terminal His-tag. |
Wesselsbron Virus NS1 protein |
|||
REC31698-500 | The Native Antigen Company | 0.5 | EUR 1890.66 |
Description: Recombinant Wesselsbron Virus NS1 protein produced in 293 human cells. Protein contains a C-terminal His-tag. |
Virus Hepatitis B Virus 320 Core Antigen (HBV 320 Core Ag) Protein |
|||
abx670003-50ug | Abbexa | 50 ug | EUR 493.2 |
Canine Distemper virus protein |
|||
30-1251 | Fitzgerald | 1 mg | EUR 400 |
Description: Purified native Canine Distemper virus protein |
Ectromelia virus protein (Mouse) |
|||
30-1263 | Fitzgerald | 1 mg | EUR 195 |
Description: Purified native Ectromelia virus protein (Mouse) |
Chikungunya virus gpE2 protein |
|||
30-1939 | Fitzgerald | 100 ug | EUR 1560 |
Description: Recombinant Chikungunya virus Glycoprotein E2 protein - wild type |
Chikungunya virus gpE1 protein |
|||
30-1940 | Fitzgerald | 100 ug | EUR 1560 |
Description: Recombinant Chikungunya virus Glycoprotein E1 protein - wild type |
Chikungunya virus gpE1 protein |
|||
30-1944 | Fitzgerald | 100 ug | EUR 1184 |
Description: Recombinant Chikungunya virus Glycoprotein E1 protein - wild type |
Canine Distemper virus protein |
|||
DAGA-473 | Creative Diagnostics | 1mg | EUR 1263.6 |
West Nile Virus NS1 protein |
|||
80-1546 | Fitzgerald | 100 ug | EUR 541.2 |
Description: Purified Recombinant West Nile Virus NS1 protein (His tag) |
West Nile Virus NS1 Protein |
|||
WNV-NS1-100 | The Native Antigen Company | 0.1 | EUR 318.94 |
Description: Recombinant West Nile Virus NS1 protein produced in 293 human cells. Protein contains a C-terminal His-tag. |
West Nile Virus NS1 Protein |
|||
WNV-NS1-500 | The Native Antigen Company | 0.5 | EUR 1305.1 |
Description: Recombinant West Nile Virus NS1 protein produced in 293 human cells. Protein contains a C-terminal His-tag. |
West Nile Virus (WNV) Protein |
|||
abx670276-50g | Abbexa | 50 µg | EUR 587.5 |
Virus Cytomegalovirus (CMV) Protein |
|||
abx670257-1ml | Abbexa | 1 ml | EUR 493.2 |
Dengue Virus Type 2 Protein |
|||
abx069813-100ug | Abbexa | 100 ug | EUR 1161.6 |
Dengue Virus Type 3 Protein |
|||
abx069814-100ug | Abbexa | 100 ug | EUR 1161.6 |
Dengue Virus Type 3 Protein |
|||
abx069815-100ug | Abbexa | 100 ug | EUR 1161.6 |
Dengue Virus Type 4 Protein |
|||
abx069816-100ug | Abbexa | 100 ug | EUR 1161.6 |
Dengue Virus Type 4 Protein |
|||
abx069817-100ug | Abbexa | 100 ug | EUR 1161.6 |
Minute Virus of Mice protein |
|||
30-1262 | Fitzgerald | 1 mg | EUR 195 |
Description: Purified native Minute Virus of Mice protein (Mouse) |
Rubella Virus E1 protein [GST] |
|||
DAGA-499 | Creative Diagnostics | 1mg | EUR 4446 |
Dengue Virus Type 2 Protein |
|||
abx670258-1ml | Abbexa | 1 ml | EUR 1345.2 |
Dengue Virus Type 2 Protein |
|||
abx069813-1g | Abbexa | 1 g | EUR 1237.5 |
Dengue Virus Type 2 Protein |
|||
abx069813-5g | Abbexa | 5 g | Ask for price |
Dengue Virus Type 3 Protein |
|||
abx069814-10g | Abbexa | 10 g | EUR 1237.5 |
Dengue Virus Type 3 Protein |
|||
abx069815-5g | Abbexa | 5 g | EUR 1237.5 |
Dengue Virus Type 4 Protein |
|||
abx069816-5g | Abbexa | 5 g | EUR 1237.5 |
Dengue Virus Type 4 Protein |
|||
abx069817-5g | Abbexa | 5 g | EUR 1237.5 |
Dengue Virus Type 2 Protein |
|||
abx670258-100g | Abbexa | 100 µg | EUR 1062.5 |
West Nile virus protein (Horse) |
|||
30-1261 | Fitzgerald | 250 ug | EUR 395 |
Description: Purified recombinant West Nile virus protein (Horse) |
Hepatitis B Virus x Protein |
|||
20-abx262147 | Abbexa |
|
|
Hepatitis C Virus E2 Protein |
|||
20-abx260782 | Abbexa |
|
|
Vaccinia virus Protein K3 (K3L) |
|||
1-CSB-EP321831VAA | Cusabio |
|
|
Description: Recombinant Vaccinia virus Protein K3 (K3L) expressed in E.coli |
Vaccinia virus Protein E3 (E3L) |
|||
1-CSB-EP322729VAA | Cusabio |
|
|
Description: Recombinant Vaccinia virus Protein E3 (E3L) expressed in E.coli |
Hepatitis B Virus x Protein |
|||
abx262147-10mg | Abbexa | 10 mg | EUR 6575 |
Hepatitis B Virus x Protein |
|||
abx262147-5mg | Abbexa | 5 mg | EUR 387.5 |
Hepatitis C Virus E2 Protein |
|||
abx260782-10g | Abbexa | 10 µg | EUR 325 |
Hepatitis C Virus E2 Protein |
|||
abx260782-2g | Abbexa | 2 µg | EUR 225 |
Potato leafroll virus Major capsid protein (ORF3) |
|||
1-CSB-EP325916PQU | Cusabio |
|
|
Description: Recombinant Potato leafroll virus Major capsid protein (ORF3) expressed in E.coli |
Japanese Encephalitis Virus Protein |
|||
abx060634-100ug | Abbexa | 100 ug | EUR 693.6 |
Japanese Encephalitis Virus Protein |
|||
20-abx260165 | Abbexa |
|
|
Japanese Encephalitis Virus Protein |
|||
abx260165-20g | Abbexa | 20 µg | EUR 950 |
Japanese Encephalitis Virus Protein |
|||
abx260165-5g | Abbexa | 5 µg | EUR 350 |
FMD Virus (NSP) Protein Antibody |
|||
abx021716-1mg | Abbexa | 1 mg | EUR 878.4 |
Hepatitis C Virus protein (HRP) |
|||
65-IH20 | Fitzgerald | 1 ml | EUR 695 |
Description: Purified recombinant Hepatitis C Virus protein (HRP) |
Hepatitis E Virus protein (HRP) |
|||
65-IH35 | Fitzgerald | 1 ml | EUR 1100 |
Description: Purified recombinant Hepatitis E Virus protein (HRP) |
Rubella virus protein (Grade 1) |
|||
30-1330 | Fitzgerald | 1 ml | EUR 786 |
Description: Purified Native Rubella virus protein (Grade 1) |
Rubella virus protein (Grade 2) |
|||
30-1331 | Fitzgerald | 1 mg | EUR 2018.4 |
Description: Purified Native Rubella virus protein (Grade 2) |
Hepatitis C Virus NS3 protein |
|||
30-AH59 | Fitzgerald | 100 ug | EUR 210 |
Description: Purified recombinant Hepatitis C Virus NS3 protein |
Hepatitis C Virus NS4 protein |
|||
30-AH60 | Fitzgerald | 200 ug | EUR 725 |
Description: Purified recombinant Hepatitis C Virus NS4 protein |
Hepatitis C Virus NS3 protein |
|||
30-AH70 | Fitzgerald | 1 mg | EUR 895 |
Description: Purified recombinant Hepatitis C Virus NS3 protein |
Rubeola virus (Level 1) protein |
|||
30-AR30 | Fitzgerald | 1 ml | EUR 341 |
Description: Purified native Rubeola virus (Level 1) protein |
Hepatitis C Virus NS3 protein |
|||
30R-AH004 | Fitzgerald | 1 mg | EUR 1818 |
Description: Purified recombinant Hepatitis C Virus NS3 protein |
Hepatitis C Virus NS4 protein |
|||
30R-AH007 | Fitzgerald | 1 mg | EUR 1400 |
Description: Hepatitis C Virus NS4 Mosaic recombinant protein |
Hepatitis C Virus NS4 protein |
|||
30R-AH008 | Fitzgerald | 100 ug | EUR 333 |
Description: Hepatitis C Virus NS4 Mosaic recombinant protein |
Hepatitis C Virus NS5 protein |
|||
30R-AH009 | Fitzgerald | 1 mg | EUR 1750 |
Description: Purified recombinant Hepatitis C Virus NS5 protein |
Hepatitis C Virus NS5 protein |
|||
30R-AH009x | Fitzgerald | 500 ug | EUR 867 |
Description: Hepatitis C Virus NS5 Genotype-1a (2322-2423) recombinant protein |
Hepatitis C Virus NS4 protein |
|||
30R-AH061 | Fitzgerald | 100 ug | EUR 840 |
Description: Hepatitis C Virus NS4 (1916-1947 a.a.) recombinant protein |
Hepatitis C Virus NS5 protein |
|||
30R-AH075 | Fitzgerald | 100 ug | EUR 1819 |
Description: Purified recombinant Hepatitis C Virus NS5 protein |